Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $38.80 Average PT from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been given an average recommendation of “Buy” by the five analysts that are presently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued a report on the stock in the last year is $38.80.

KNSA has been the topic of several analyst reports. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Wedbush reaffirmed an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price target on the stock.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, Director Barry D. Quart sold 12,336 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $30.39, for a total transaction of $374,891.04. Following the transaction, the director now owns 12,546 shares of the company’s stock, valued at $381,272.94. This trade represents a 49.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ross Moat sold 18,259 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the transaction, the insider now owns 9,415 shares in the company, valued at $191,030.35. The trade was a 65.98% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 443,906 shares of company stock valued at $12,081,708 over the last quarter. Company insiders own 54.57% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after buying an additional 568 shares during the period. US Bancorp DE purchased a new position in Kiniksa Pharmaceuticals in the first quarter valued at approximately $33,000. Asset Management One Co. Ltd. purchased a new position in Kiniksa Pharmaceuticals in the first quarter valued at approximately $41,000. Wealthquest Corp purchased a new position in Kiniksa Pharmaceuticals in the first quarter valued at approximately $42,000. Finally, Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $61,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Trading Up 2.1%

Shares of NASDAQ KNSA opened at $28.30 on Friday. Kiniksa Pharmaceuticals has a 52 week low of $17.38 and a 52 week high of $30.69. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -202.13 and a beta of 0.06. The company’s 50-day moving average price is $25.12 and its 200 day moving average price is $22.17.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $137.79 million for the quarter, compared to analysts’ expectations of $128.35 million. During the same period last year, the company earned ($0.25) EPS. The firm’s revenue for the quarter was up 72.5% compared to the same quarter last year. As a group, research analysts expect that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.